


RespiFinder® 19/22

A PCR based Multiplex assays to detect
19 or 22 respiratory pathogens in a single assay



Overview

Acute respiratory tract infection (RTI) is the most wide-spread type of acute infection in adults and children and is a significant cause of morbidity in immunocompromised patients. Both viruses and bacteria can cause acute RTI, and the number of causative pathogens is large as well as diverse. Multiparameter Real Time PCR based tests provide a fast and accurate means of molecular diagnostics. RespiFinder® assays are ready to use sets of primers, probes and enzymes for the simultaneous detection and differentiation of 19 or 22 respiratory pathogens, based on size fractionation. RespiFinder® assay have the same sensitivity as multiplex Real Time PCR assays.

Products

RespiFinder® 19 - 50 reactions
PF0200-M (Compliant with ABI CE systems)

RespiFinder® 19 Cy5 - 50 reactions
PF0250-M (Compliant with Beckman Coulter CE systems)

RespiFinder® 22 - 50 reactions
PF0500-M (Compliant with ABI CE systems)

Targets

Influenza virus A	Rhinovirus/*Enterovirus
Influenza virus B	Parainfluenza-1
*Influenza A H1N1v	Parainfluenza-2
**Influenza A H5N1	Parainfluenza-3
RSV-A	Parainfluenza-4
RSV-B	Adenovirus
Human Metapneumovirus	Coronavirus NL63
Legionella pneumophila	*Coronavirus HKU1
Bordetella pertussis	Coronavirus 229E
Mycoplasma pneumoniae	Coronavirus OC43
Chlamydomphila pneumoniae	*Bocavirus

* Only included in the RespiFinder® 22 assay

** Only included in the RespiFinder® 19 and 19 Cy5 assays

Diagnostic specimens

- Nasopharyngeal aspirate/lavage
- Swab
- Bronchoalveolar Lavage (BAL)
- Sputum (after sample pretreatment)

Quality

- Validated on QCMD panels
- Validated on clinical samples
- **CE**-IVD marked
- Designed and produced under ISO13485:2003

Procedure

Despite the developments in conventional PCR, the complexity of multiplex PCR is still limited. The MultiFinder® technology is PathoFinder's proprietary multiplex PCR technology enabling the detection and differentiation of up to 22 pathogenic (RNA and DNA) targets in a single molecular diagnostic assay by means of size fractionation.

After a gene-specific multiplex reverse transcription step, two unique probes hybridize specifically to the DNA of each pathogen present in the clinical specimen. Hybridized probes are joined by a ligation step and subsequently amplified using a universal PCR primer pair of which one primer is labelled with a fluorescent dye (FAM/Cy5).

The total length of an amplified probe is unique and specific for a particular pathogen and can be detected by size fractionation. An Internal Amplification Control (IAC), which is added at the start of the procedure, is included in the assay to validate a negative sample result.

For more information about the MultiFinder® technology or other products, please visit our website:

www.pathofinder.com.

Detection systems

- ABI Genetic Analyzers (Applied Biosystems)
- CEQ systems (Beckman Coulter)

References

RespiFinder: a New Multiparameter Test To Differentially Identify Fifteen Respiratory Viruses;
Martin Reijans et al.; Journal of Clinical Microbiology, 2008, Vol. 46; p. 1232–1240.

